Phillips Medisize announced that it officially integrated Vectura into its business, expanding its capabilities in inhaled therapies.
At the start of the year, the company completed its acquisition of Vectura from a subsidiary of cigarette maker Philip Morris. Vectura enables Phillips Medisize to offer a wider range of formulation, device design, combination product development and manufacturing services.
The acquisition includes Vectura’s proprietary technology and combination product development expertise in dry powder inhalers (DPI). That includes the lever operated multi-dose inhaler (LOMI) and Gyrohaler platforms, plus metered dose inhalers (MDI). It also adds nasal inhalers and nebulizers to the portfolio.
Vectura also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies and regulatory services. These capabilities enhance pharmaceutical R&D services and expands Phillips Medisize’s capabilities in inhalation drug delivery.
Phillips Medisize plans to unveil new developments in inhaled therapies at the Respiratory Drug Delivery (RDD) conference in Lisbon, Portugal this week.
“Combining the strengths of Vectura and Phillips Medisize has amplified our ability to innovate and deliver cutting-edge solutions that support the evolving needs of patients and pharmaceutical partners alike,” said Dr. Geraldine Venthoye, chief scientific officer. “We look forward to continuing to shape the landscape of inhaled drug delivery as we leverage our formulation, device and combination product development expertise with new abilities to commercialize products through the Phillips Medisize global supply chain and production network. At RDD, we are excited to connect with our industry colleagues about the future of inhalation science and product development.”
